Clinical Trials Logo

Clinical Trial Summary

This protocol describes a feasibility pilot study preceding a randomized clinical study that aims at comparing the Elipse intragastric Balloon system to other invasive obesity techiniques.

The current pilot study is investigating the feasibility and efficacy of the Elipse Balloon system in 20 patients in Norway.


Clinical Trial Description

The primary aims of the pilot study are to streamline the infrastructure, machinery, and clinical experience with the balloon before the start of the randomized trial. The inclusion and exclusion criteria, and measurement points will be similar for the two studies.

The primary endpoints of the pilot study are to ascertain the feasibility of

1. Patient recruitment and informed consent process

2. Balloon insertion procedure

3. Follow-up of patients for the period of balloon therapy (one balloon)

4. Data gathering, data management, and endpoint evaluation

5. Adverse event evaluation of balloon insertion and therapy Secondary endpoints are weight loss, HBA1c

Eligible Patients Eligible patients are adults who have been referred for obesity treatment to one of the participating obesity centres and meet all of the inclusion criteria and none of the exclusion criteria.

Inclusion criteria

1. adults 18 year or older with BMI ≥30 and ≤40 kg/m2, and a diagnosis of type 2 diabetes.

Feasibility of the intervention will be assesssed by the investigators. Subjects will be carefully monitored during the study for possible adverse events (AEs) and will be advised to contact the study investigator in case of symptoms of possible adverse events.. During each clinical follow-up visit, the investigator will determine AE occurrences. Each adverse event is considered to be either anticipated or unanticipated as described below.

An AE is any adverse change from the subject's baseline (pre-treatment) condition, including a concurrent illness, occurring during the course of the study whether or not considered related to the study intervention (balloon or surgery). Therefore, an AE can be any unfavorable and/or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the procedure.

All adverse events are described by the local study investigator using the electronic patient record system at the participating site. Adverse events will also be collected once yearly through searches in local and national patient registries (hospital discharge and diagnosis registry, Norwegian cause-of-death registry, Norwegian cancer registry).

AEs are categorized as serious or non-serious. Serious Adverse Event (SAE) are those leading to

- unplanned medical or surgical intervention

- unplanned hospitalization (including emergency department visit)

- prolonged duration of planned hospitalization (>24hrs)

- life threatening illness or injury

- permanent impairment of a body structure or a body function

- Death Planned hospitalization for a pre-existing condition, or a procedure required by the protocol, without serious deterioration in health, is not considered a serious adverse event.

Non-Serious Adverse Events:

Adverse events that do not meet the definition of SAEs.

AE evaluation Each reported SAE is reviewed by an adverse event evaluation committee. The committee consist of three individuals with a medical background relevant for the trial and its interventions. The committee is not blinded to treatment arm as this is not feasible given the nature of the trial interventions and the expected grade of details to review to make a decision. Each member of the AE evaluation committee reviews each case independently. Agreement of whether the SAE is due to the intervention or not (yes, no, An SAE report is submitted to the PIs and the company one time each year during the course of the trial.

Participants will be examined by the study investigators 1 to 3 weeks prior to treatment start (baseline visit), and at weeks 4, 8, 12, 16, 26 and 52 after treatment start.

At the baseline visit, demographic data and medical history is assessed.

All visits include a clinical examination with measurements of body weight, anthropometric measures and blood pressure, laboratory analyses, a registration of supplementation and prescription and over-the-counter drug use, and registration of complications and side effects.

Body weight and composition will be measured with patients wearing light clothing and no shoes using bioelectrical impedance analysis. Anthropometric measures will be recorded with patients in an upright position. Height will be measured using wall mounted stadiometers; waist circumference (WC) will be measured at the point midway between the lowest rib margin and the iliac crest. Height and circumferences will be measured to nearest 0.5 cm and weight to the nearest 0.1 kg.

The following laboratory analysis will be performed: hemoglobin; white blood cell count; platelet count; international normalized ratio; C-reactive protein; blood glucose, HbA1c; insulin, C-peptide; anti-GAD; anti-IA2; sodium; potassium; phosphate; chloride; magnesium; serum iron; ferritin; transferrin; calcium; 1,25 dihydroxyvitamin D; 25 hydroxyvitamin D; parathyroid hormone; thiamine; B12; folate; creatinine; bilirubin; albumin; total protein; alanine aminotransferase; aspartate aminotransferase; alkaline phosphatase A; gamma-glutamyl transpeptidase; amylase; lactate dehydrogenase; triglycerides; total cholesterol; HDL cholesterol; LDL cholesterol; unbound thyroxine; thyroid stimulating hormone; ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03576833
Study type Interventional
Source Norwegian Department of Health and Social Affairs
Contact Michael Bretthauer, MD PhD
Phone 90132480
Email michael.bretthauer@medisin.uio.no
Status Recruiting
Phase N/A
Start date May 15, 2018
Completion date December 31, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Recruiting NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT03255005 - Endomina Controlled Study N/A
Enrolling by invitation NCT03063606 - Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment Phase 2/Phase 3
Terminated NCT03299881 - Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss N/A
Completed NCT03317587 - Inspiring Nutritious Selections and Positive Intentions Regarding Eating and Exercise (INSPIRE) N/A
Not yet recruiting NCT03569774 - Individualized vs Low PEEP in One Lung Ventilation N/A
Active, not recruiting NCT03610958 - Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss. N/A
Completed NCT02235961 - Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects Phase 1
Completed NCT03195712 - Metabolically Healthy Obesity: Correlations Between BMI and Metabolic Syndrome Biomarkers N/A
Recruiting NCT00341406 - Fat Cell Size in Insulin Resistance
Not yet recruiting NCT03538236 - Intragastric Balloon With Lifestyle Intervention vs. Lifestyle Intervention in Obese Patients With NASH N/A
Not yet recruiting NCT03470272 - Effects of Red Light LED Therapy on Body Contouring N/A
Recruiting NCT03627104 - Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity N/A
Recruiting NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Active, not recruiting NCT02918279 - Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity Phase 3
Completed NCT00494767 - Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs Phase 1
Recruiting NCT03338296 - Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years Phase 4